<DOC>
	<DOCNO>NCT00996476</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness , safety pharmacokinetics ( Explores body medication ) TMC435350 combination Peginterferon Alfa-2a Ribavirin genotype 1 hepatitis C virus infect Japanese participant never receive treatment hepatitis C infection .</brief_summary>
	<brief_title>A Study Assess Effectiveness , Safety , Pharmacokinetics TMC435 Combination With Peginterferon Alfa-2a Ribavirin Hepatitis-C Infected Patients</brief_title>
	<detailed_description>This Phase 2 , randomize ( The study medication assign chance . ) , 5-arm , open label ( All people know identity intervention . ) , multicentre ( study conduct multiple site ) study . Approximately , 84 participant randomize 5 different arm 2:2:1:1:1 ratio . In treatment arm 1 2 , participant receive 12 week triple therapy ( use 3 medication ) TMC435 50 100 mg daily plus Peginterferon Alfa-2a Ribavirin follow 12 week treatment Peginterferon Alfa-2a Ribavirin . In treatment arm 3 4 , participant receive 24 week triple therapy TMC435 50 100 mg daily plus Peginterferon Alfa-2a Ribavirin . In treatment arm 5 ( control group ) , participant receive Peginterferon Alfa-2a Ribavirin 48 week . This study consist screen phase upto 6 week , treatment phase upto 48 week post treatment follow-up period 24 week . Safety evaluation include assessment adverse event , clinical laboratory test , vital sign , cardiovascular safety .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants document chronic hepatitis C infection evidence presence HCV antibody least 6 month ( 180 day ) prior inform consent . Participants genotype 1 HCV infection . Participants plasma HCV RNA level â‰¥ 5.0 log10 IU/mL screening . Participants diagnose hepatic cirrhosis hepatic failure . Participants liver disease hepatitis C. Participants infection/coinfection nongenotype 1 HCV .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Interferon Alfa-2a</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Viral RNA</keyword>
</DOC>